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ABBREVATIONS: 
ALS, amyotrophic lateral sclerosis; CNBD, cyclic nucleotide-binding domain; Dig, 
Digoxigenin; HA, hemagglutinin; HCN channels, Hyperpolarization-activated cyclic-
nucleotide-gated channels; hpf, hours post fertilization; IML, intermediolateral nucleus; ISH, 
in-situ hybridization; MO, Morpholino-modified antisense oligonucleotides; Pir, piriform 
cortex; RTh, reticular thalamic nucleus; Sth, subthalamic nucleus; TC, thalamocortical 
neurons; TEVC, Two-electrode voltage-clamp; VAMP, vesicle-associated membrane protein; 
VAPB, VAMP-Associated Protein B; VB, ventrobasal thalamic complex; Y2H, Yeast Two-
Hybrid 
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ABSTRACT: Hyperpolarization-activated cyclic-nucleotide-gated (HCN) channels 
encode neuronal and cardiac pacemaker currents. The composition of pacemaker 
channel complexes in different tissues is poorly understood and the presence of 
additional HCN modulating subunits was speculated. Here we show that VAMP-
Associated Protein B (VAPB), previously associated with a familial form of amyotrophic 
lateral sclerosis 8 (ALS8), is an essential HCN1 and HCN2 modulator. VAPB 
significantly increases HCN2 currents and surface expression and has a major influence 
on the dendritic neuronal distribution of HCN2. Severe cardiac bradycardias in VAPB-
deficient zebrafish and VAPB
-/-
 mice highlight that VAPB physiologically serves to 
increase cardiac pacemaker currents. An altered T-wave morphology observed in ECGs 
of VAPB
-/-
 mice supports the recently proposed role of HCN channels for ventricular 
repolarization. The critical function of VAPB in native pacemaker channel complexes 
will be relevant for our understanding of cardiac arrhythmias, epilepsies, and provides 
an unexpected link between these diseases and ALS.  
 
 
KEY WORDS: HCN channels · VAPB · ALS · pacemaker · cardiac arrhythmia   
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INTRODUCTION 
Hyperpolarization-activated cyclic-nucleotide gated (HCN) channels play a major role in 
generating neuronal and cardiac automaticity (1). Upon hyperpolarization HCN channels 
induce an unspecific cationic conductance, mediated by Na
+
 and K
+
 (2), described as Ih and Iq 
in the brain or If in the heart. These pacemaker currents regulate the heart rate (3), as well as 
rhythmic activity in neuronal circuits (4, 5) and synaptic transmission (6), but are also 
important for setting the resting membrane potential (7). The conserved cyclic-nucleotide-
binding-domain (CNBD) in the C-terminus of HCN channels (8) confers a cAMP-sensitivity 
to the channels (9, 10) which can be antagonized by an allosteric competition with the 
auxiliary HCN subunit Trip8b (11, 12). However, remaining differences in voltage-
dependence and pharmacology of pacemaker currents in native tissues towards the four 
known HCN channels suggest the presence of additional HCN channel modulating proteins.  
Here, we describe a novel interaction partner and modulator of HCN1 and HCN2, the 
vesicle-associated membrane protein (VAMP)-associated protein B (VAPB or ERG30) (13). 
VAPs were initially described as interacting partners of VAMP, participating in 
neurotransmitter release (14). VAPs are, in addition to the ER, found in many intracellular 
compartments including i.e. the Golgi apparatus, recycling endosomes, tight junctions, but 
also the plasma membrane (15, 16). Both family members, VAPA (VAP-33) (17) and VAPB 
form a complex via their transmembrane domains and are part of the vSNARE complex (16). 
It has been proposed that VAPB is not directly participating in synaptic vesicle exocytosis, 
but rather in the targeting of components to the synaptic terminals (18). In addition, previous 
studies of Kv2.1 and VAMP (19), TASK-1 and syntaxin 8 (20) or GLUT4 and VAPA (15) 
indicated that components of the vSNARE or tSNARE complex might have functions besides 
regulating exocytosis, as they modulate channels or transporters which are integral to the 
surface/cell membrane. 
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MATERIALS and METHODS 
 
Split-ubiquitin Yeast Two-Hybrid experiments 
 
A split-ubiquitin Yeast Two-Hybrid membrane protein system (Y2H Membrane Protein Kit, 
MoBiTec, Göttingen, Germany) was used for screening a NubG fused human brain cDNA 
library in the yeast strain NMY51 to identify potential interaction partners of HCN2. For this 
purpose full-length mHCN2 was subcloned by SfiI restriction sites into the bait vector pBT3-
N according to the instruction manual (MoBiTec, Göttingen, Germany). pAl-Alg5 was used 
as positive control and pPR3-N as negative control. Yeast clones were selected by activation 
of reporter genes upon positive interaction of bait (pBT3-mHCN2) and prey (NubG-x fused 
cDNA library) encoding two auxotrophic growth markers (HIS3 and ADE2). Activation of 
reporter genes concedes yeast clones to grow on minimal medium lacking histidine (H), 
adenine (A), leucine (L) and tryptophan (W) for selection (-LWHA medium). Further 
selection for the strongest interactors was performed by a β-galactosidase assay due to the 
property of positive colonies expressing the protein β-galactosidase. Isolated plasmid-DNA of 
positive yeast colonies was analyzed by sequencing. For the confirmation of interaction, a 
split ubiquitin Yeast-Two-Hybrid direct interaction assay was performed. Therefore, full-
length hVAPB was subcloned via SfiI restriction sites into the prey vector pPR3-N and tested 
for an interaction with pBT3-mHCN2 or pBT3-hHCN4 by validation of colony growth on 
minimal medium (-LWHA). 
 
Expression constructs 
 
For oocyte expression hHCN1, mHCN2, hHCN4 and hVAPB were subcloned into pSGEM. 
NTK
HCN2 was cloned into ALMV vector and mHCN2
HAEx into pBF1. cRNA was prepared 
with mMessage mMachine T7 or SP6 Kit (Ambion, Thermo Fisher Scientific, Waltham, MA) 
after linearization. QuikChange (Stratagene, Biocompare, South San Francisco, CA) 
mutagenesis kit was used to introduce specific mutations. hVAPB, hVAPA, hVAMP1 and 
hVAMP2 were subcloned in frame into the pGEX-4T-1 vector (Amersham, GE Healthcare, 
Freiburg, Germany) for GST-fusion protein expression in BL21 cells. VAPB and VAPA were 
subcloned via EcoRI and SalI, whereas VAMP1 and VAMP2 were subcloned with BamHI 
and EcoRI. Constructs for mammalian cell expression were subcloned in pEGFP, pDsRed or 
pcDNA3.1(+) vectors. 
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GST pull-down experiments 
 
GST-fusion proteins were obtained after lysis of 1 ml BL21 cell culture. Protein expression 
was induced at 0.4-0.6 OD600 by 1 mM IPTG for 3 h at 37 °C. Protein extraction of a 1 ml 
culture was performed using 200 µl RIPA buffer supplemented with 4 µl protease inhibitor 
cocktail (PIC) (Sigma-Aldrich, Merck, München, Germany) and 1% lysozyme. Six freeze and 
thaw cycles were performed to improve the protein yield. HCN2 protein was prepared by lysis 
of HeLa cells transfected with 2 µg HCN2
EGFP
. HeLa cells were harvested 48 h after 
transfection, washed in PBS and lysed 30 min on ice using 200 µl RIPA buffer supplemented 
with 10 µl PIC (Sigma-Aldrich, Merck, München, Germany). Insoluble material was 
separated by centrifugation (13.000 rpm for 15 min at 4 °C). TnT® Quick Coupled 
Transcription/Translation System (T7, Promega, Madison, WI) was used to synthesize in vitro 
translated HCN2 based on HCN2 pcDNA3.1 plasmid using T7 promotor. Pull-down 
experiments were performed following the MagneGST Pull-Down System (Promega, 
Madison, WI) manual. Proteins were eluted from magnetic beads with 20 µl 2x SDS sample 
buffer. For separation of the proteins by SDS-PAGE, pull-downs were heat denatured at 40 
°C for 10 min. After centrifugation at 5.000 rpm for 3 min protein lysates were separated on a 
8% SDS-polyacrylamide gel. The input illustrated in Fig. 1C-D was diluted 1:15 and 1:10 in 
Fig. 1F. Proteins were transferred to a nitrocellulose membrane via a Semi-Dry Transfer Cell 
(Biorad, Müchen, Germany) at 70 mA for 1 h. For GST pull-downs with HCN2
EGFP
, the 
HCN2 protein was visualized by immunoblotting with mouse α-GFP antibody (#ab290, 
1:5000, abcam, Cambridge, United Kingdom). The binding of the primary antibody was 
detected using peroxidase-conjugated goat α-rabbit IgG antibody (#32460, 1:2000, Pierce 
Thermo Scientific, Waltham, MA) and a chemiluminescent extended-duration substrate 
(Super Signal West Dura, Thermo Scientific, Waltham, MA). Untagged HCN2 protein was 
detected with rabbit α-HCN2 antibody (#APC-030, 1:300, Alomone, Jerusalem, Israel) and 
peroxidase-conjugated goat α-rabbit IgG antibody (#32460, 1:2000, Pierce Thermo Scientific, 
Waltham, MA) as the secondary antibody. 
 
Two-electrode voltage-clamp (TEVC) measurements in Xenopus oocytes 
 
Isolation of Xenopus laevis oocytes and TEVC recordings were performed as previously 
described (21). Stage IV and V oocytes were injected with 7.5 ng of HCN2 cRNA or co-
injected with 1 ng of VAPB, VAPB
P56S
, VAPA, VAPC, VAMP1 and VAMP2, as well as 1 ng 
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of the following VAPB mutations: TM
VAPB
, MSP
VAPB
, MSP-CC0.5
VAPB
 and MSP-CC
VAPB
. For 
the C-terminal deletion constructs
 
3.5 ng 
NTK
HCN2, HCN2
F530*
 and HCN2
V628*
 or 15 ng of 
HCN2
F486*
were co-expressed with 1 ng VAPB. To determine selectivity within HCN-channel 
family members 3.5 ng HCN1 or 15 ng HCN4 cRNA was co-expressed with 1 ng VAPB. 3.5 
ng HCN2 was co-expressed with 0.25 ng VAPA/B complex. TEVC experiments were 
performed in ND96 solution, containing (in mM): NaCl 96, KCl 2, CaCl2 1.8, MgCl2 1, 
HEPES 5; pH 7.4, 2 days after injection of the respective constructs. ND66 solution, 
containing (in mM): NaCl 66, KCl 32, CaCl2 1.8, MgCl2 1, HEPES 5; pH 7.4, was used for 
the co-expression experiments of VAPB with HCN4, HCN2
F486*
 and the complex 
measurements of HCN2 and VAPA/B, due to small current amplitudes. IV-curves were 
recorded by two second voltage steps to potentials ranging from -30 mV to -140 mV from a 
holding potential of -30 mV. Tail currents were recorded by a 750 ms test pulse to -130 mV. 
 
Inside-out macropatch clamp recordings from Xenopus laevis oocytes 
 
Giant patch recordings in the inside-out configuration under voltage-clamp conditions were 
made at room temperature (22 - 24 °C). Pipettes were made from thick-walled borosilicate 
glass, had resistances of 0.3 - 0.5 MΩ (tip diameter of 5 - 15 µm) and were filled with a 
pipette solution containing (in mM): KCl 120, HEPES 10 and CaCl2 1.0; pH 7.2. Bath 
solutions had the following composition (in mM): KCl 100, HEPES 10, K2EGTA 10; pH 7.2. 
Bath solutions were applied via a multi-barrel pipette system to the cytoplasmic side of 
excised membrane patches. Currents were recorded with an EPC10 amplifier (HEKA 
electronics, Lambrecht, Germany) and capacitive transients were compensated with an 
automated circuit of the EPC10. 
 
Fluorescence microscopy 
 
HeLa or HL-1 cells were grown on 35 mm glass bottom Petri dishes (Willco, Amsterdam, 
Netherlands) to a confluency of about 50%. HeLa cells were grown in DMEM medium 
containing 10% fetal bovine serum (Invitrogen, Thermo Scientific, Waltham, MA) and 1% 
Pen Strep (Life Technologies, Darmstadt, Germany). After 24 h, HeLa cells were transfected 
with either 1 µg EGFP-C1-HCN2-HAEx (
EGFP
HCN2
HAEx) or co-transfected with VAPB 
pcDNA3.1 or TM
VAPB
 pcDNA3.1 per dish using Jetprime (Peqlab, Erlangen, Germany). Cells 
were maintained at 37 °C for 6 - 48 h aerated with 5% CO2. For fluorescence imaging HL-1 
8 
 
cells were fixed with methanol, while for HeLa cells live cell imaging in a HBSS buffer 
(Invitrogen, Thermo Scientific, Waltham, MA) was performed. Fixed HL-1 cells were stained 
with an α-VAPB antibody (#sc-98992, 1:50, Santa Cruz, Heidelberg, Germany) after 
permeabilization (0.25% Triton-X-100/PBS) and blocking with 3% goat serum/PBS. For 
visualization an Alexa Fluor 488 goat α-rabbit antibody (#A11008,1:200, Invitrogen, Thermo 
Scientific, Waltham, MA) was used. Fluorescence microscopy was performed with an 
Olympus IX71 microscope equipped with a 60× N.A. 1.3 PL APO objective or a 100× N.A. 
1.4 PL APO objective (Olympus, Hamburg, Germany), standard EGFP/Texas Red filter sets 
and a cooled 12-bit CCD camera (SensiCam QE). During live cell imaging, cells were 
maintained at 37 °C using an objective heater (Bioptechs, Butler, PA). Digital images were 
processed using Image-Pro Plus 6.0 (MediaCybernetics, Cambridge, United Kingdom). 
 
Analyses of channel surface expression in oocytes and HeLa cells and Western blot 
analysis 
 
Xenopus laevis oocytes were injected with 10 ng HCN2
HAEx cRNA transcribed from pBF1 
alone or co-expressed with 1 ng VAPB 48 h before surface expression analysis. Subsequently, 
a chemiluminescence assay was performed as previously described (21).  
For surface expression studies in HeLa cells, cells were grown to a confluency of 90% and 
transfected with either 1 µg 
EGFP
HCN2
HAEx
 alone or co-transfected with 1 µg VAPB 
pcDNA3.1 or TM
VAPB
 pcDNA3.1. Cells were fixed with 4% PFA for 20 min on ice and 
blocked with 10% normal goat serum/PBS with 0.1% sodium azide for 1 h at room 
temperature. Immunolabeling was performed with an α-HA antibody (#sc-7392, 1:100 in 
PBS, Santa Cruz, Heidelberg, Germany) for 1 h followed by 4 times washing in PBS. After 
incubation with a peroxidase-coupled secondary antibody (#sc-2005, α-goat, 1:5000, Santa 
Cruz, Heidelberg, Germany) luminescence was measured in a luminometer (GloMax® 20/20, 
Promega, Madison, WI) by addition of chemiluminescence substrate (SuperSignal ELISA 
Femto Maximum Sensitivity Substrate, Thermo Scientific, Waltham, MA). Peak 
luminescence was determined and normalized to 
EGFP
HCN2
HAEx mean luminescence. For 
determination of the whole cell protein concentration, cells were lysed with RIPA buffer as 
previously described. Equal amounts of protein lysates verified by Bradford assay were 
separated on a 10% SDS-polyacrylamide gel with Mini-PROTEAN Tetra Cell (Biorad, 
Müchen, Germany) at 35 mA and transferred to a nitrocellulose membrane for Western blot 
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analysis. 
EGFP
HCN2
HAEx
 was detected with an α-GFP antibody (#ab290, 1:5000, abcam, 
Cambridge, United Kingdom). 
 
 
Preparation and transfection of primary cortical neurons 
 
Primary cultures of cortical neurons were prepared from embryonic Sprague-Dawley rats 
(E16) (Rattus norvegicus) essentially as previously described (22). Primary cortical neurons 
were seeded at a density of 200.000 cells/well (24 well plates) onto polylysine-coated 
coverslips in Neurobasal A medium supplemented with 2% B27, 1 µg/µl gentamycin, 2 mM 
glutamax, and 5% FCS. After 4 h, this medium was replaced with Neurobasal medium 
supplemented with 1.2 mM glutamine, 2% (v/v) B27 supplement (20 ml/l) and 
penicillin/streptomycin (0.1 mg/ml) which was used as a culture medium. Following 3-DIV, 
neurons were transfected with 1 µg HA-tagged VAPB (
HA
VAPB) or 
HA
VAPB
P56S
 plasmid 
using 2 µl/ml Lipofectamine2000 (Invitrogen, Thermo Scientific, Waltham, MA) according to 
the manufacturer’s instructions.  
Images were acquired using a confocal laser scanning microscope (Leica SP5, Wetzlar, 
Germany). Light was collected through a 63x 1.4 NA oil immersion lens with an additional 
2× optical zoom applied for dendritic regions. For green detection, cells were excited at 488 
nm and 543 nm and emissions were detected using 505-530 band pass filter (green), Alexa 
568 stained HCN2 or VAPB was detected by excitation at 620 nm band pass filter and 
emission by using a 690 nm long pass filter (red). 
 
In-situ hybridization 
 
To generate specific ISH probes cDNA fragments of HCN2 (nt. 1404-1934, NM_008226.2), 
VAPA (nt. 894-1462, NM_013933.3) and VAPB (nt. 3299- 4320, NM_019806.5) were 
obtained by RT-PCR cloning from RNA extracts of mouse brain and subcloned into pGEM-T 
(Promega, Madison, WI) for in vitro transcription. Specific primer sets are listed in 
Supplemental Table 1. 14 µm thick frozen brain sections were cut on a LEICA cryostat, thaw-
mounted on adhesive slides and subjected to the pre-hybridization procedure as described. 
Digoxigenin (Dig)-labeled probes in anti-sense and sense orientation were generated from the 
templates described above by in vitro transcription using SP6 or T7 RNA polymerase in a Dig 
labeling mix containing 10 mM each of ATP, CTP, and GTP, 6.5 mM UTP and 3.5 mM 
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digoxigenin-11-UTP (Roche, Mannheim, Germany). Riboprobes in sense-orientation served 
as negative controls. After limited alkaline hydrolysis (0.2 M Na2CO3, pH 10.2) probes were 
added to the hybridization solution (3× SSC, 50 mM Na3PO4, 10 mM dithiothreitol, 1× 
Denhardt's solution, 0.25 g/l yeast tRNA, 10% dextran sulfate, and 50% formamide) to a final 
concentration of 0.1 to 0.5 ng/μl. To each slide 50 µl hybridization mix was applied and 
incubated for 14 h at 60 °C. Slides were washed in 2× SSC for 20 min, followed by 30 min 
RNase A treatment [20 μg RNase A and 1U/ml RNase T1 (Roche, Mannheim, Germany) in 
10 mM Tris-HCl, pH 8.0, 0.5 M NaCl, and 1 mM EDTA] at 37 °C. The slides were washed at 
room temperature in decreasing salt concentrations (1, 0.5, and 0.2× SSC) for 20 min each 
and at 60 °C in 0.2× SSC for 1 h, followed by a final rinse at room temperature in 0.2× SSC 
and distilled water for 10 min each. For hybrid detection slides were equilibrated for 30 min at 
room temperature in buffer A (100 mM Tris and 150 mM NaCl, pH 7.5) containing 0.05% 
Tween 20 (Merck, Darmstadt, Germany) and blocking reagent (Roche, Mannheim, Germany). 
Alkaline phosphatase-conjugated anti-Dig Fab fragments (#11093274910, Roche, Mannheim, 
Germany) were diluted to 0.25 U/ml in blocking buffer and applied to slides for 2 h at 37 °C. 
Excessive antibody was removed by two 10 min washes in buffer A. Slides were equilibrated 
to buffer B (100 mM Tris, 100 mM NaCl, and 50 mM MgCl2; pH 9.4) containing 0.05% 
Tween 20 for 10 min. The chromogen solution containing 0.2 mM 5-bromo-4-chloro-3-
indolyl phosphate and 0.2 mM nitroblue tetrazolium salt (Roche, Mannheim, Germany) in 
buffer B was applied for 3 to 12 h in the dark, under periodic microscopic monitoring of color 
development, until reaction was stopped in water. Slides were embedded in aqueous mounting 
medium (Merck, Darmstadt, Germany). Only adult (3 - 6 months) in house bred male 
C57BL6/J mice were used (n = 4). Each ISH experiment was performed three times and for 
each brain region investigated nine to twelve sections (equals three to four slides) were 
hybridized with anti-sense probes and six sections (two slides) with sense probes. For analysis 
and documentation an Olympus AX70 fluorescence microscope (Olympus Optical, Hamburg, 
Germany) equipped with a SPOT digital camera system (Diagnostics Instruments Inc, 
Sterling Heights, MI) was used.  
 
VAPA and VAPB knock-down experiments in embryonic zebrafish 
 
Zebrafish (Danio rerio) of the Tübingen strain were bred and maintained at 28.5 °C as 
described by Westerfield (23). Pictures and movies were recorded at 72 hours post 
fertilization (hpf). Heart rate was counted at 72 hpf at room temperature. For all Morpholino-
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modified antisense oligonucleotide injection procedures, the TE wild-type strain was used. 
Morpholino-modified antisense oligonucleotides (MO) (Gene Tools, LLC, Philomath, OR) 
were directed against the translational start site (5’-TCAGGATCTGCTCCAGTTTGGACAT-
3’) of zebrafish VAPA (MOVAPA), and the translational start site (5’-CCATCTCCCACTGC-
AAACGCTCGGA-3’) of zebrafish VAPB (MOVAPB). For rescue experiments, sense-capped 
cRNAs of human wild-type VAPA as well as wild-type and mutant VAPB
P56S
 were 
synthesized using the mMESSAGE mMACHINE system (Ambion, Thermo Fisher Scientific, 
Waltham, MA). Each cRNA was, with a concentration of 75 ng/µl, co-injected with 
MO
VAPB 
or KCl. Calcium imaging was performed as previously described (24, 25). Wild-type and 
MOVAPA/VAPB morphant embryos were injected with 1 nl of a 250 μM stock solution of 
calcium green-1 dextran (Molecular Probes) at the one-cell stage. At 72 hpf videos were 
recorded with a Proxitronic (Proxivision, Bensheim, Germany) camera at 29.97 frames per 
second. Relative fluorescence of the atrium and ventricle were analyzed with custom-made 
software (26). All zebrafish injection procedures were repeated at least three times (three 
biological replicates). All surviving injected embryos per group were subjected to functional 
analyses at 72 hpf.  
 
Immunostaining of VAPB in embryonic zebrafish hearts 
Dissected hearts of 72 hpf old zebrafish embryos were fixed in 4% methanol-free 
formaldehyde in PBS. After blocking in 10% goat-serum in PBST, hearts were incubated with 
a custom made rabbit polyclonal anti-mouse VAPB antibody (1:2000), previously described 
(37), for 1 h at RT. The secondary antibodies were diluted 1:1000 in PBST and incubated for 
30 min at RT. For documentation a Zeiss Axioskop2 plus and the Axio Vision software 
(Zeiss, Wetzlar, Germany) was used. 
 
RT-PCR and in-situ hybridization 
 
RNAs from embryonic zebrafish hearts were extracted using the RNeasy
®
 Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Reverse transcription was 
performed by using SuperScript
®
 III Reverse Transcriptase (Life Technologies, Darmstadt, 
Germany). Vapa- and vapb-specific PCR analyses were carried out according to standard 
protocols using SYBR-Green master mix (Roche, Germany) and a Roche LightCycler 480 II. 
Whole-mount in-situ hybridization was performed using Digoxigenin-labelled antisense RNA 
probes against zebrafish vapa and vapb as previously described. 
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ECGs in VAPB
-/-
 mice 
 
Non-invasive surface ECGs from adult VAPB (+/+, +/-, -/-) mice (C57Bl/6N tac strain) 
gently restrained by an ECG tunnel system (EMKA Technologies, Paris, France) were 
recorded by contact electrodes inserted in the tunnel floor in conscious mice. VAPB knock-
out mice were backcrossed over five generations and for the experiments wild-type littermates 
served as control. All parameters were measured from lead I by blinded observers. 
 
Experiments in HL-1 cells 
 
HL-1 cells were grown on 35 mm dishes (Nunc, Thermo Fisher Scientific, Waltham, MA) to 
a confluency of about 50%. Cells in each dish were either transfected with 2 µg pEGFP vector 
alone, or in combination with 2 µg VAPB pcDNA3.1(+) or 2 µg pcDNA3.1(+). For knock-
down experiments HL-1 cells were transfected with either 2 µg shVAPB-GIPZ or 2 µg 
shcontrol-GIPZ. For Western blot analysis of HL-1 cardiomyocytes, the cells were treated 
with puromycin to select for transfected cells. After 24 hours, HL-1 cells were measured with 
an EPC10 amplifier (HEKA electronics, Lambrecht, Germany) in the whole-cell 
configuration at room temperature (22 °C) using previously described solutions (27). Pipettes 
had a tip resistance of 2.5 - 4.0 MΩ when filled with a solution for If recordings containing (in 
mM): KCl 120, TEA-Cl 10, Na2GTP 0.4, Na2ATP 5, MgCl2 2, EGTA acid 11, CaCl2 5 and 
HEPES 5; pH 7.2. Cells were bathed in modified Tyrode solution containing (in mM): NaCl 
140, KCl 25, MgCl2 1.2, CaCl2 1.8, glucose 10, NiCl2 2, BaCl2 2, 4-aminopyridine 0.5 and 
HEPES 5; pH 7.4. Series resistances were automatically compensated by 70%. IV-
relationships were recorded by 1.5 s voltage steps ranging from -20 mV to -120 mV in 20 mV 
increments, recorded from a holding potential of -30 mV with a sweep time interval of 10 s. 
Tail currents were elicited by a 300 ms step to -110 mV.  
For action potential measurements HL-1 cells were grown to 100% confluency and action 
potentials were measured in the current clamp mode without electrical stimulation. Pipettes 
had a resistance between 2.5 - 4.0 MΩ, when filled with a solution containing (in mM): KCl 
60, K-glutamate 65, Na2GTP 0.2, K2ATP 3, MgCl2 2, EGTA 5, and HEPES 5; pH 7.2. 
Whole-cell measurements were obtained at room temperature in a bath solution containing (in 
mM): NaCl 135, KCl 5, MgCl2 1, NaH2PO4 0.33, glucose 10, Na-pyruvate 2, CaCl2 1 and 
HEPES 10; pH 7.4. 
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Slice patch clamp experiments of neurons of the piriform cortex and the thalamus 
 
Animals were sacrificed under isoflurane anesthesia and brain tissue was rapidly removed 
from the skull. Thalamic coronal slices (250 µm) were prepared from VAPB
-/-
 and C57Bl/6N 
tac mice (p90-p120) on ice-cold oxygenated (O2) saline solution, containing (in mM): sucrose 
200, PIPES 20, KCl 2.5, NaH2PO4 1.25, MgSO4 10, CaCl2 0.5, dextrose 10; pH 7.35. Slices 
were transferred to a chamber with an artificial cerebrospinal fluid (ACSF) containing (in 
mM): NaCl 125, KCl 2.5, NaH2PO4 1.25, NaHCO3 24, MgSO4 2, CaCl2 2, dextrose 10; and 
kept for 30 min at the temperature of 30-32 ºC and further at room temperature until the 
recording time. pH was adjusted to 7.35 by constant aerating with carbogen (95% O2 and 5% 
CO2). Ih was recorded in the whole-cell mode from thalamocortical neurons (TC) of the 
ventrobasal thalamic complex (VB) and pyramidal neurons of piriform cortex (Pir). Slices 
were transferred to a recording chamber with an external solution (bath solution) containing 
(in mM): NaCl 120, KCl 2.5, NaH2PO4 1.25, HEPES 30, MgSO4 2, CaCl2 2, dextrose 10; pH 
7.25. Recordings were performed at 30 ± 1 ºC. Patch pipettes were pulled from borosilicate 
glass (GC150T-10; Clark Electromedical Instruments, Kent, United Kingdom) and had 
resistances of 3 - 5 MΩ. The pipette solution contained (in mM): K-gluconate 95, K3-citrate 
20, NaCl 10, HEPES 10, MgCl2 1, CaCl2 0.5, BAPTA 3, MgATP 3, Na2GTP 0.5; pH 7.25 
and 295 mOsm/kg. All recordings were made from the soma of the neurons using an EPC10 
amplifier (HEKA electronics, Lambrecht, Germany). The access resistance was in a range of 
5 - 25 MΩ and was monitored throughout the whole experiment. Cells with access resistance 
more than 25 MΩ were discarded. Series resistance compensation of >30% was applied. 
Voltage-clamp experiments were controlled by the software Pulse or PatchMaster (HEKA 
electronics, Lambrecht, Germany). Measurements were corrected for a liquid junction 
potential of 10 mV. The protocol used for assessment of Ih current is as described previously 
(5). Briefly, Ih current was measured by hyperpolarizing steps of -10 mV increment from a 
holding potential of -40 to -130 mV.  
 
Immunohistochemistry of HCN channels in the piriform cortex 
 
Twenty to thirty day-old mice C57BL/6NTac were transcardially perfused with 4% PFA. 
Brains were removed and post fixed for 2 hours in 4% PFA and later in 30% sucrose for 48 
hours. Free-floating coronal sections (40 µm) were cut and slices were collected in phosphate-
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buffered saline (PBS). Sections were washed 3 times for 10 min in PBS, preincubated for 20 
minutes in PBS containing 0.3% Triton-X100. Slices were then incubated for 2 hours in 6% 
normal goat serum in PBS/Triton-X100 0.3%. Slices were incubated with primary antibodies: 
rabbit(rb)-anti-HCN1 (#APC-056, 1:200), rb-anti-HCN2 (#APC-030, 1:200), rb-anti-HCN4 
(#APC-052, 1:200) (Polyclonal rabbit-antibodies, Alomone labs, Israel) and guinea pig (gp)-
anti-Map2 (#188004, 1:100, Synaptic Systems, Germany) for 48 hours at 4 °C. After 
incubation with the primary antibody, slices were washed 3 times for 10 minutes in PBS and 
thereafter transferred to the secondary antibody solution (Alexa Fluor 568 goat anti-gp-IgG, 
#ab175714, 1:1000 and Alexa Fluor 488 goat anti-rb-IgG, #ab150113, 1:1000) for one hour, 
washed 3 times thereafter for 10 min and mounted with a mounting medium 
(VECTASHIELD with DAPI, Vector Laboratories Inc., Burlingame, CA, USA) for confocal 
microscopy. 
 
Patch clamp recordings of INa and ICa in iPSC-derived cardiomyocytes 
 
Whole-cell patch clamp experiments for measurement of Ca
2+
 and Na
+
 currents were 
performed in murine iPSC-derived cardiomyocytes (iPSC-CMs, commercially available from 
Axiogenesis AG, Cologne, Germany, http://axiogenesis.com/). Cells were seeded in 35 mm 
glass bottom dishes (MatTek, Ashland, MA) coated with laminin and fibronectin at a density 
of 2x10
4
 cells per dish. Cells were incubated at 5% CO2 and 37 °C with CorAt media. Cells 
were transfected with pEGFP empty vector (200 ng) either with pcDNA3.1(+) vector (1 µg) 
as control or with VAPB pcDNA3.1(+) (1 µg) using Lipofectamin 3000 (Invitrogen, Thermo 
Scientific, Waltham, MA) following manual instructions. Currents were measured 48-72 
hours after transfection with glass electrodes (1.5-5 MΩ) filled with intracellular solution 
containing (in mM): NaCl 8, CsAsp 120, TEA-Cl 20, MgCl2 5.9, HEPES 20 and K2ATP 5, 
pH 7.2. An EPC-10 amplifier (Heka electronics, Lambrecht, Germany) and the Fitmaster 
program (Heka electronics, Lambrecht, Germany) was used for data acquisition. For 
measurements of the Ca
2+
 currents (ICa), cells were kept in normal tyrode solution (in mM: 
NaCl 140, KCl 5.4, MgCl2 1.1, HEPES 5, glucose 10, CaCl2 1.8, pH 7.4) supplemented with 
CsCl (5 mM). Whole-cell currents were recorded from a holding potential of −80 mV, using a 
500 ms voltage-ramp from -80 mV to -40 mV to inactivate sodium currents before I-V 
measurements. Starting from a test potential of -40 mV, cells were clamped to different 
voltages in 400 ms steps ranging from -50 mV to +40 mV in 10 mV increments. Sodium 
currents (INa) were elicited in a bath solution containing (in mM): NaCl 20, NMDG 120, KCl 
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4, MgCl2 1, CaCl2 1.8, HEPES 5, glucose 10, pH 7.4, supplemented with 5 µM nifedipine. 
Whole-cell currents were recorded from a holding potential of −80 mV followed by 100 ms 
voltage steps from -80 mV to +40 mV in 5 mV increments. 
 
Patch clamp recordings of Cav1.3 in HEK293 cells 
 
HEK293 cells were cultured in 25 cm
2
 flasks at 37 °C and 5% CO2 in DMEM (Invitrogen, 
Thermo Scientific, Waltham, MA) supplemented with 10% FCS and 1% 
penicillin/streptomycin solution (Invitrogen, Thermo Scientific, Waltham, MA). At a 
confluency of 60 - 70%, cells were transiently transfected with complementary DNA 
encoding Cav1.3 α1-subunits (human, 6 µg/flask) together with auxiliary β2b (human, 3 
µg/flask) and α2δ1-subunits (human, 3 µg/flask), EGFP (0.5 µg/flask) and empty vector 
(pcDNA3.1(+), 3 µg/flask) or VAPB (human, 3 µg/flask) using JetPRIME (Peqlab, Erlangen, 
Germany). Cells were subsequently kept at 30 °C and 5% CO2. 48 h after transfection cells 
were detached using 0.05% trypsin and transferred to 35-mm Petri dishes for 
electrophysiological recordings. Whole-cell patch-clamp recordings were performed at room 
temperature with an EPC10 amplifier (HEKA electronics, Lambrecht, Germany ) using 
electrodes pulled from borosilicate capillaries with a resistance of 2 - 5 MΩ. Series resistance 
was compensated by 50%. The extracellular solution contained 110 mM NaCl, 20 mM CsCl, 
10 mM BaCl2, 10 mM HEPES, 1 mM MgCl2 and 10 mM glucose (pH 7.4). The pipette 
internal solution contained 130 mM KCl, 10 mM NaCl, 0.5 mM MgCl2, 1 mM EGTA and 5 
mM HEPES (pH 7.3). Current–voltage (I–V) relationships were obtained by applying a 300 
ms long square pulse protocol to various test potentials starting from a holding potential of -
80 mV. 
 
Cell culture 
 
HEK293 and HeLa cells were obtained from Sigma-Aldrich
®
 and mouse iPSC-CMs from 
Axiogenesis
®
 which were not authenticated again after commercial purchase. HL-1 cells were 
previously obtained by Prof. Claycomb and authenticated by their electrophysiological 
properties (21). All cells were probed for mycoplasma contamination. 
 
Quantification and statistical analysis 
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Statistics were performed as previously described (28). Briefly, every dataset for wild-type 
and each mutant and for every current/kinetical feature analyzed was tested with a Shapiro-
Wilk test for normality. Equality of variances was tested using either a parametric or non-
parametric Levene's test. In case of similar variances, significance was probed using either a 
paired or unpaired Student´s t-test and for not normally distributed data, a non-parametric 
Mann-Whitney U-test and a Wilcoxon signed-rank test for paired analyses was used, 
respectively. If the variances of the groups were different, significance was probed using 
either Welch’s t-test and for not normally distributed data Mood’s median test was used. 
Experiments were non-randomized and non-blinded and no pre-specified sample size was 
estimated. For inclusion/exclusion criteria, only dead embryonic zebrafish were excluded 
from the statistics. For experiments using VAPB
-/-
 mice, we have based estimated differences 
on previous data and calculations of sample size assuming 1 – β = 0.80 and α = 0.05. To 
detect changes in ECG recordings, at least eight animals per genotype were used, to ensure 
adequate power to detect 20-30% change. All alive and healthy looking littermate animals 
were examined. ECG recordings of all examined mice was high enough in quality for 
analyzing heart rate, PQ interval, QT interval and duration of QRS complex following pre-
established criteria. T-wave morphology analysis of three mice had to be excluded because 
signals were divergent from pre-established criteria. The order of taking ECGs recordings was 
randomized to consecutive order following cage numbers which were marked by the animal 
facility. The investigators performing and analyzing the ECGs were blinded to the genotype. 
 
Ethical Approval 
 
The investigation conforms to the Guide for the Care and Use of Laboratory Animals (NIH 
Publication 85-23). All experimental procedures were performed in accordance with the 
principles approved by local authorities (review board institution: Landesamt für Natur, 
Umwelt und Verbraucherschutz Nordrhein-Westfalen, Germany; approval IDs: 84-
02.04.2015.A574, 84-02.05.50.15.026 and 887-50 10 37 09.125) or the UK Home Office 
(PPL number 30/2967). Efforts were made to minimize the number of animals and the degree 
of discomfort to animals used in this study. 
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RESULTS 
 
VAPB selectively increases HCN1 and HCN2 pacemaker currents 
 
Using a split-ubiquitin Yeast Two-Hybrid (Y2H) (29) screen with the full-length HCN2 
channel as a bait to search for plasma membrane bound channel modulators, we identified 
from a human adult brain cDNA library VAPB as a potential HCN2 interacting partner. From 
458 clones that grew under drop out conditions 35 clones contained VAPB. In contrast, 
VAPA, the closest relative of VAPB, was not fished from the human brain cDNA library. 
Y2H direct-interaction assays confirmed an interaction of VAPB with HCN2, but not HCN4 
(Fig. 1A). VAP proteins are anchored with a C-terminal transmembrane domain (TM) in the 
cell membrane, contain a conserved N-terminal major sperm region (MSP) and an 
amphipathic coiled-coil domain (CC), which is a common motif in tSNAREs (30) (Fig. 1B). 
The VAPB fragments identified through the Y2H screen include the TM and parts of the CC, 
but not the MSP domain (Supplemental Fig. 1). GST pull-down experiments confirmed an 
interaction of HCN2 with VAPB (Fig. 1C), but also the close family member VAPA and the 
VAP-interacting partners VAMP1 and VAMP2 (Fig. 1D). Using HCN2 transfected HeLa 
cells 
GST
VAPA pulled down HCN2 together with endogenously expressed VAPB, suggesting 
that HCN2 channels might be in a complex with VAPA and VAPB (Fig. 1E). VAPB and 
VAPA both directly interact with in vitro translated HCN2, albeit the physical interaction 
with VAPA seems to be more efficient (Fig. 1F). Pull-down experiments with in vitro 
translated HCN2 confirmed also a direct interaction with VAMPs (Fig. 1F). Most 
importantly, both 
GST
VAPA and 
GST
VAPB pulled down HCN2 from rat brain protein lysates 
(Fig. 1G).  
The co-expression of HCN2 with low amounts of VAPB in Xenopus oocytes strongly 
increased current amplitudes (Fig. 1H, I). HCN1 current amplitudes were also increased (Fig. 
1J), while HCN4 was not modulated, consistent with our interaction analyses (Fig. 1A, J). 
None of the other tested potassium channels were influenced by VAPB, revealing a selectivity 
for HCN1 and HCN2 channels (Fig. 1K). To further support this observation, we performed 
patch clamp experiments of mouse iPSC cardiomyocytes (iPSC-CMs) transfected with 
VAPB, to probe for effects of VAPB on cardiac sodium and calcium channels. Here VAPB 
transfection did not alter inward sodium (INa) or calcium (ICa) currents (Supplemental Fig. 2A-
F and Material and Methods). In addition, as these iPSC-CMs rather reflect ventricular 
cardiomyocytes than sino-atrial pacemaker cells, we also excluded that VAPB modulates 
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Cav1.3, a channel highly relevant for sino-atrial pacemaking (Supplemental Fig. 2G-I). The 
VAP family contains an alternative spliced isoform, VAPC, lacking the CC and the TM 
domains (17, 31). Whereas VAPA also mildly increases the HCN2 current amplitudes, VAPC 
has no modulatory effect (Fig. 1L and Supplemental Fig. 3). Strikingly, co-expressing HCN2 
together with VAPA and VAPB led to a similar and slightly more pronounced current 
increase (Fig. 1M), compared to VAPB co-expressed alone (Fig. 1L). Albeit the current 
increase was not significantly larger, the effect was more robust (compare HCN2 + VAPB, 
p<0.01 versus HCN2 + VAPA/VAPB, p<0.001) (Fig. 1L, M). 
VAPB did not alter the voltage-dependence of HCN2 activation (Supplemental Fig. 4A) or 
the activation kinetics (Supplemental Fig. 4B), a similar lack of effects was observed for 
VAPA and VAPC (Supplemental Fig. 3). As effects of VAPB on the voltage-dependence of 
activation might be missed due to the high cAMP-levels intrinsic to oocytes, we performed 
inside-out macropatch clamp recordings from oocytes to directly control intracellular cAMP 
concentrations. However, also in inside-out patches and in absence of intracellular cAMP, 
VAPB did not influence the voltage-dependence of activation (Fig. 1N-Q). In addition, 
application of 100 µM cAMP maximally shifted the voltage-dependence of activation in a 
similar manner, as for HCN2 alone, indicating that there is no effect of VAPB on the cAMP-
modulation of the channels (Fig. 1N-Q).  
Next, we investigated the mechanism for the increased HCN2 current amplitudes. The 
current amplitudes of HCN2, now harboring an extracellular HA-epitope (HCN2
HAEx) was 
increased, similar as described for the untagged protein (Fig. 1R). The surface expression in 
the same oocytes, probed with a chemiluminescence-assay (ELISA), exclusively detecting 
channels at the plasma membrane, revealed that the increased current amplitudes are mainly 
caused by an increased surface expression of the channels (Fig. 1R, S).  
The previously described VAPB
P56S
 mutation located in the MSP domain causes ALS8 and 
late onset spinal muscular atrophy (32). Co-expression of VAPB
P56S
 with HCN2 revealed that 
the ALS-causing mutation lost its ability to increase the HCN2 current amplitudes (Fig. 1T). 
 
Domains mediating the interaction of VAPB with HCN2 
 
A split-ubiquitin Y2H direct-interaction assay introducing different premature stop codons in 
HCN2 revealed that the CNBD and the entire C-terminus are dispensable for the interaction 
with VAPB and that the N-terminus of HCN2 together with the S1 segment is sufficient for 
the interaction (Fig. 2A, B and Supplemental Fig. 5). These data are supported by functional 
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studies (Fig. 2C) in which VAPB still increased the current amplitudes of HCN2 channels 
which lack the entire C-terminus (HCN2
F486*
) (Fig. 2C). In contrast, current amplitudes of 
HCN2 channels with an N-terminal deletion (
NTK
HCN2) (33) were no longer modulated by 
VAPB (Fig. 2D). Consistently, the 
NTK
HCN2
HAEx current amplitude (Fig. 2E) and surface 
expression (Fig. 2F) were not altered by VAPB. Similar effects were obtained replacing the 
N-terminus of HCN2 by that of HCN4 (
HCN4-N
HCN2) which also results in a loss of VAPB 
modulation (Fig. 2G).  
Next, we probed which parts of VAPB mediate the functional effects on HCN2. 
Surprisingly, the transmembrane segment of VAPB alone (TM
VAPB
) is sufficient to increase 
HCN2 currents (Fig. 2H), while the MSP domain alone or in combination with the CC 
domain (MSP+CC
VAPB
) is ineffective. These data are consistent with the lack of HCN2 
modulation by VAPC which lacks the TM domain (17). Confirming the role of the 
transmembrane segment for channel modulation, also the HCN2
HAEx current amplitudes (Fig. 
2I) and surface expression (Fig. 2J) were increased by TM
VAPB
. 
 
VAPB determines surface expression and dendritic localization of HCN2 
 
Co-transfection of N-terminally tagged HCN2
HAEx (
EGFP
HCN2
HAEx) with VAPB or TM
VAPB
 
resulted in increased fluorescence at the plasma membrane (Fig. 3A). For these recordings 
untagged VAPB was used, as fluorescent protein tags have been described to cause a 
dimerization of VAPB (34, 35). The increased surface expression was quantified detecting 
HCN2 channels at the cell membrane using non-permeabilized, fixed cells and an ELISA 
assay, recognizing the extracellular HA-epitope of the 
EGFP
HCN2
HAEx construct. Consistent 
with the data from the oocyte expression system (Supplemental Fig. 1 and Fig. 2F, J), an 
increased surface expression of HCN2 was observed in the presence of VAPB or TM
VAPB
 
(Fig. 3B, C). Next, we probed whether the effects of VAPB on HCN2 surface expression are 
caused by alterations in channel endocytosis. Therefore, we either used dynasore or the C-
terminus of the adaptor protein 180 (AP180C), a construct that blocks clathrin-mediated 
endocytosis (20, 36). Here, despite inhibiting endocytosis by dynasore or AP180C, VAPB 
increased the HCN2 surface expression with a similar efficiency (Supplemental Fig. 6A-C). 
Taken together, these data support that enhanced surface expression of HCN2 is most likely 
caused by a more efficient forward transport of the channel to the plasma membrane. As 
HCN2 currents and surface expression are also increased by a minimal VAPB protein 
(TM
VAPB
), with a single transmembrane domain (Fig. 2H-J and Fig. 3A, C), the most 
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straightforward explanation is that VAPB may be part of the native HCN channel complex 
which is more efficiently transported to the membrane. 
Next, we analyzed the endogenous HCN2 expression in primary cortical neurons after 
transfection with HA-tagged VAPB (
HA
VAPB) (Fig. 3D). Here, HCN2 and transfected 
HA
VAPB strongly co-localized in the dendrites and the soma of the neurons (merge to white). 
In contrast, the transfected ALS8 mutation 
HA
VAPB
P56S
 aggregates in the soma, consistent 
with previous studies (34) (Fig. 3E). Most importantly, HCN2 fluorescence is now primarily 
located in the soma and a loss of distribution into the dendrites can be observed, albeit the 
dendrites of the neurons are still intact, as visible from the MAP2 staining of 
HA
VAPB
P56S
 
transfected neurons (Fig. 3E). 
 
Co-distribution of VAPs with HCN2 and contribution to thalamic Ih 
 
Furthermore, we investigated the distribution of VAPB, VAPA and HCN2 mRNAs in mouse 
brain and spinal cord by in situ hybridization (ISH) experiments (Fig. 4A-E). In general, 
VAPB hybridization signals were weaker than those for VAPA. Highest VAPB mRNA levels 
were detected in the piriform cortex (Pir) (Fig. 4A), the CA3 region of the hippocampus (Fig. 
4B), the hypothalamic arcuate and ventromedial nucleus and in medial habenulae (Fig. 4B, 
C). An overlapping distribution of VAPB and HCN2 was noted in many brain regions (Fig. 
4A-E), particularly evident in the reticular thalamic nucleus (RTh) and globus pallidus (Fig. 
4C). Hybridization signals for all three transcripts were observed in the subthalamic nucleus 
(Sth), the ventrobasal thalamic nucleus (Fig. 4C), the habenulae (Fig. 4B, C), but also the 
spinal cord (Fig. 4E). 
While the distribution of VAPB and HCN2 mRNA expression was very similar in all 
regions examined (Fig. 4A-E), the VAPA mRNA expression pattern was in some brain 
regions only partially overlapping. For example, Purkinje cells of the cerebellar cortex 
express relative high mRNA levels for VAPA, but only very low levels for HCN2 and VAPB 
(Fig. 4D). Most importantly, the observed co-expression of VAPB with HCN2 in the 
abovementioned neurons is in perfect agreement with the functional interaction we describe. 
Consistent with a thalamic co-expression of HCN2 and VAPB and the role of VAPB to 
increase macroscopic HCN2 and HCN1 currents, patch clamp experiments in neurons of the 
ventrobasal thalamus of VAPB
-/-
 mice (37) revealed significantly reduced Ih current 
amplitudes (Fig. 4F, G). While Ih current amplitudes were reduced (Fig. 4F, G), no major 
effects on the voltage-dependence of activation were observed (Fig. 4H). In addition, we 
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performed patch clamp experiments of neurons of the piriform cortex which have in contrast 
to the ventrobasal thalamus a pronounced expression of HCN1 and reduced HCN4 levels 
(Supplemental Fig. 7A-C and Material and Methods). Here, we only found a minor reduction 
of Ih current amplitudes and the voltage-dependence was not significantly altered 
(Supplemental Fig. 7D-G). However, the speed of activation was slowed (Supplemental Fig. 
7H) which is consistent with a reduced relative contribution of HCN1 channel to native Ih 
currents in the piriform cortex. The fact that kinetics change, while the overall Ih amplitudes 
largely remain unaltered, indicates that there might be upregulation of other channels or 
subunits after VAPB knock-out. 
 
Bradycardia in knock-down zebrafish embryos and VAPB
-/-
 mice 
 
In-situ hybridization and RT-PCR experiments using zebrafish hearts at 72 hpf, revealed a 
cardiac expression of both VAPA and VAPB in the embryonic heart (not illustrated). Using 
whole-heart immunostainings, VAPB expression was evident throughout the atrium and 
ventricle of the embryonic zebrafish heart (Supplemental Fig. 8A-B). Subsequently, to 
elucidate the functional role of VAPs for cardiac pacemaking in vivo, we inactivated either 
VAPB or VAPA using Morpholino-modified antisense-oligonucleotides (MO), targeting the 
translation initiation site of zebrafish VAPA (
MO
VAPA) or VAPB (
MO
VAPB) (Fig. 5A-F). 
Knock-down of either VAPA or VAPB did not cause structural heart defects (data not 
shown). For 
MO
VAPB a mild and for 
MO
VAPA a pronounced pericardial edema was observed 
(Fig. 5A). Moreover, in both types of morphant zebrafish embryos a bradycardia was evident 
(Fig. 5B), with 101 ± 12 bpm for VAPA morphants and 125 ± 10 bpm for 
MO
VAPB-injected 
embryos, compared to control-injected embryos with 153 ± 5 bpm. As a proof for the 
specificity of the knock-down, the heart rate of 
MO
VAPB-injected embryos could be rescued 
by the concomitant injection of either VAPA or VAPB cRNA (Supplemental Fig. 8C-D). 
Note that the injection of cRNA for the human VAPB
P56S
 mutant into zebrafish embryos did 
not cause a significant reduction of the heart rate (Supplemental Fig. 8E), indicating that the 
construct does not act in a dominant-negative manner on zebrafish If current components. 
Although heart rate was significantly reduced in VAPA and VAPB morphants, both cardiac 
chambers, atrium and ventricle, contracted regularly and sequentially as in wild-types, 
whereby each atrial contraction was followed by a ventricular contraction, indicating 
unaffected atrio-ventricular conduction. Bradycardia was even more severe when VAPA and 
VAPB were simultaneously inactivated (
MO
VAPA/B) and
 
VAPA/VAPB morphants had 
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severely reduced heart rates (55 ± 41 bpm). In contrast to the VAPA or VAPB morphants, the 
double knock-down of VAPA and VAPB led to a broad heart rate variability (Fig. 5D, E) and 
in 20% of all morphant embryos to severe heart rhythm disturbances (n = 20) (Fig. 5F). To 
evaluate if abnormal cardiac excitation propagation or excitation-contraction-coupling 
account for bradycardia and heart rhythm disturbance, we monitored free cytosolic 
myocardial calcium and cardiac contraction simultaneously. In 80% of VAPA/VAPB 
morphants (n = 20) cardiac excitation starts in the atrium, and propagates from the atrium 
towards the ventricle, evident as each atrial calcium wave is followed by a calcium wave 
through the ventricle (Fig. 5D, E). In addition, each calcium wave is accompanied by cardiac 
chamber contraction (not illustrated), indicating that cardiac excitation in VAPA/VAPB 
morphants is appropriately initiated in the atrium, but with a reduced frequency compared to 
controls. As described above, in 20% of all 
MO
VAPA/B-injected embryos conduction 
abnormalities were observed (n = 20). We found atrio-ventricular blocks, where not every 
atrial excitation causes ventricular excitation, as evident from Fig. 5F illustrating a 2:1 atrio-
ventricular block. The excitation-contraction coupling of VAPA/VAPB morphants was intact, 
indicating that knock-down of VAPA/VAPB only impairs the initiation of excitation in the 
atrium and the atrio-ventricular conduction which is likely to correlate to a QT time 
prolongation in mice. 
Tail-cuff measurements of VAPB
-/-
 mice detected a prominent heart rate reduction (Fig. 
5G) which did however not result in altered blood pressure (Supplemental Fig. 9). Surface 
ECG recordings of VAPB
-/-
 mice (Fig. 5H-N; and Supplemental Fig. 10 and Supplemental 
Fig. 11) revealed a sino-atrial bradycardia (Fig. 5H, I), as heart rates were reduced while the 
duration of the PQ interval, corresponding to atrio-ventricular conduction, was unchanged 
(Fig. 5J, K). However, the QTc interval (Fig. 5L) was prolonged by about 8%. In addition, 
the Tpeak-Tend (Tp-Tec) interval (Fig. 5M) was prolonged and the JT-wave amplitude (JTp) was 
increased (Fig. 5N and Supplemental Fig. 11), effects that were also observed for mice with 
genetically impaired HCN channels (38).  
 
VAPB modulates If of spontaneously beating cardiac HL-1 cells 
 
Next, we studied the effects of VAPB in HL-1 cells, a spontaneously beating sino-atrial node 
like cardiomyocyte cell line (39). HL-1 cells endogenously express VAPB (Fig. 6A) which 
was efficiently diminished by shRNA-mediated knock-down (Fig. 6B). Overexpression of 
VAPB in HL-1 cells accelerated spontaneous beating rates (Fig. 6E), consistent with 
23 
 
increased If amplitudes. As previously reported, not all HL-1 cells express macroscopic If 
currents (27). However, we found 1.5-fold more often If-containing cells, when HL-1 cells 
were transfected with VAPB (Fig. 6D). Strikingly, the kinetics of channel activation was 
accelerated by VAPB (Fig. 6C, F) and the voltage-dependence of If was shifted by +10 mV 
(Fig. 6G, H). This effect can be explained by increased HCN1 and HCN2 current amplitudes 
and thus a decreased relative contribution of HCN4 to If in this cell line. Conversely, shRNA-
mediated knock-down of VAPB significantly reduced the spontaneous action potential 
frequency (Fig. 6I, K), by a prolongation of the diastolic depolarization phase (Fig. 6I, J). 
Norepinephrine treatment of HL-1 cells increased the beating frequency and, also under these 
conditions, VAPB knock-down strongly reduced the beating frequency (Supplemental Fig. 
12). Strikingly, VAPB knock-down had the opposite effects on current kinetics and voltage-
dependence, as VAPB overexpression. VAPB knock-down slowed the activation time 
constants (Fig. 6L) and led to more hyperpolarized V1/2 values (-9 mV) (Fig. 6M, N). These 
in vitro data confirm that VAPB serves to increase macroscopic If currents in sino-atrial cells, 
providing an explanation for the sino-atrial bradycardia observed in VAPB
-/-
 mice.  
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DISCUSSION 
 
As VAPB specifically serves to increase both HCN1 and HCN2 current amplitudes, the 
knock-out of VAPB results in a similar or even more severe sino-atrial bradycardia than 
knock-out of the murine HCN1 or HCN2, respectively (40, 41). All HCN isoforms are 
expressed in the working myocardium (38) and recently an unexpected contribution to the late 
repolarization phase of the ventricular action potential has been postulated (38, 42, 43). In this 
case, HCN3
-/-
 mice presented with strong changes in T-wave morphology and a mild (12%) 
QT-interval prolongation (38). The transmural gradient, with an increased T-wave amplitude, 
resulted from an action potential duration (APD) shortening selective for epicardial 
cardiomyocytes. This transmural effect on APD was also present in HCN1
-/-
 mice (38). The 
mechanism behind this epicardial-specific APD shortening, and why concomitantly a QT-
interval prolongation is present, remained elusive. Strikingly, VAPB
-/-
 mice presented a 
similar phenotype, indicating that VAPB is also an essential component of the ventricular If 
channel complex (38). Thus, in the future, detailed regional action potential studies are 
indicated in VAPB
-/-
 mice to further investigate this phenomenon. In addition, VAPB might 
be relevant for inherited forms of ventricular arrhythmias or for arrhythmias in heart failure, 
where increased ventricular If current densities are discussed as a major trigger (43). So far 
congenital arrhythmias have only been associated with HCN4, the predominant sino-atrial 
HCN transcript. Possibly human mutations affecting either HCN1 or HCN2 are compensated 
by the other isoform, preventing a cardiac phenotype. It is conceivable that only a combined 
reduction of HCN1 and HCN2 current in sino-atrial cells leads to a cardiac phenotype. Similar 
as for Bartter syndrome Type IV, where the auditory phenotype is only observed when 
Barttin, the subunit for both ClC-K chloride channels (ClC-Ka and ClC-Kb) is genetically 
impaired (44), mutations in VAPB might be responsible for cardiac arrhythmias that were not 
found for HCN1 or HCN2 channels alone.  
A major question arising from our results is whether this novel function of VAPB in 
regulating HCN1 and HCN2 activities could be involved in motor neuron disease. Indeed, 
gene mutations of VAPB have been found in several families developing ALS8, a motor 
neuron disease also affecting the autonomic nervous system (32, 45), and loss of the VAPB 
protein occurs in neurons from ALS8 patients (46) as well as in motor neurons of sporadic 
ALS patients (47). Importantly, the P56S mutation of VAPB leads to a loss of HCN activity 
(Fig. 1T). Thus, mutant VAPB, as well as loss of VAPB, might lower dendritic Ih, primarily 
encoded by HCN1 and HCN2 in motor neurons (48, 49), thereby decreasing excitability of 
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motor neurons. Indeed, increasing motor neuron excitability is protective for motor neurons 
during ALS (50, 51) (reviewed in (52)). Thus, the loss of VAPB in motor neurons, while not 
sufficient to trigger ALS in mice or zebrafish (37), could substantially contribute to motor 
neuron degeneration through decreased excitability. On the other hand, the effects might vary 
by neuron type and brain region. For instance, in the cortex and hippocampus, loss of 
dendritically-localized Ih is expected to lead to a hyperexcitability.   
Arrhythmias and sudden cardiac death (SCD) are common in ALS (53). SCD is 
responsible for about twenty percent of the death cases in ALS patients (54, 55). ALS patients 
suffer from prolonged QTc intervals with increased QTc dispersion (54), a dysregulation of 
the heart rate (56) and have a 25% increased prevalence for atrio-ventricular block (57). 
However, VAPB mutations are very rare and only one Brazilian family was investigated in 
depth (58). In this family, there was no evidence of cardiac arrhythmia, and to our knowledge, 
no patient with a VAPB mutation and typical ALS, as described by Nishimura et al. (32), has 
been studied for cardiac function. On the other hand, as VAPA and VAPB are reduced in 
ALS patients (34), a dysregulation of HCN channels might be also relevant for sporadic or 
other familial forms of ALS. The arrhythmias and effects on QTc interval are thought to 
primarily result from a degeneration of sympathetic neurons of the intermediolateral nucleus 
(IML) (54). Thus, a reduced sympathetic activity could mask an intrinsic bradycardia, due to a 
dysregulation of HCN channels. In addition, in ALS patients, afflicted by a severe and life 
threatening disorder and with the motor symptoms dominating, a bradycardia with less 
psychological strain might have frequently not been brought to the attention of the physicians.  
HCN channels in the brain are modulated by Trip8b (PEX5R) (59) which reduces the 
cAMP-responsiveness of HCN2 and HCN4 (12), but not of HCN1 channels (60). In addition, 
however, Trip8b also produces a larger increase in maximal Ih by cAMP (61). The proximal 
N-terminus of Trip8b is alternatively spliced and differentially controls HCN trafficking and 
function, with the most prominent neuronal Trip8b isoform enhancing HCN1 channel surface 
expression (62). This HCN channel modulation is mediated by an interaction with the cyclic-
nucleotide binding-domain (63) or the distal C-terminus (59), while the entire C-terminus is 
dispensable for the interaction of HCN1 and HCN2 with VAPB. Thus, although VAPB and 
Trip8b both serve to increase surface expression of HCN channels, they act via different 
binding domains. In addition, VAPB does not cause a modulation of the cAMP-
responsiveness of HCN channels. Although the two proteins bind to different regions of the 
pacemaker channels, it is prompting to analyze whether these subunits act in a synergistic 
manner or whether there is functional interplay with the Trip8b effects on channel gating. 
26 
 
We conclude that VAPB is an essential regulator of neuronal and cardiac pacemaker 
channels, modulating the surface expression and cellular localization of HCN2 and HCN1 
channels. Therefore, VAPB is likely to play a role in HCN-mediated processes like the 
regulation of cellular excitability, dendritic integration and transmission of synaptic potentials 
(64). VAPB modulation of HCN channels might be highly relevant for our understanding of 
many diseases such as cardiac arrhythmias, epilepsies, inflammatory or neuropathic pain and 
amyotrophic lateral sclerosis (32, 64).  
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FIGURE LEGENDS 
 
Figure 1. VAPB selectively increases HCN1 and HCN2 currents. A) Y2H direct interaction 
assay. Transformation control (-LW), leucine and tryptophan dropout. Interaction read-out 
(-LWHA), additional dropout of histidine and adenine. pAL-Alg5, positive control. pPR3-N, 
negative control. B) Topology of VAPB. MSP, major sperm protein domain; CC, coiled-coil 
domain; TM, transmembrane segment. C) 
GST
VAPB pull-down of HCN2
EGFP
 using 
transfected HeLa cells. D) 
GST
VAPA, 
GST
VAMP1 or 
GST
VAMP2 pull-down of HCN2
EGFP
 
using transfected HeLa cells. E) 
GST
VAPA pull-down of HCN2 and endogenous VAPB, using 
HCN2
EGFP
 transfected HeLa cells. F) Pull-down of in vitro translated HCN2 (untagged). G) 
Pull-down of HCN2 from rat brain lysates. H) Representative currents of HCN2 expressed in 
oocytes alone or with VAPB and I) the relative current amplitudes analyzed over three days. 
J) Relative currents of HCN1, HCN2 and HCN4 alone or co-expressed with VAPB. K) 
Relative currents of different potassium channels co-expressed with VAPB and of L) HCN2 
co-expressed with VAPA, VAPB or VAPC. M) Relative currents of HCN2 co-expressed with 
a mixture of VAPA/B (1:1). N) Representative macropatch recordings in different 
configurations: on cell (o.c.), inside-out after patch excision (i.o.) and after application of 100 
µM cAMP (i.o.+100 µM cAMP). O) Activation curves for HCN2 alone (n = 6) recorded as in 
N) or P) after co-expression with VAPB (n = 8). Q) V1/2 values for HCN2 expressed alone or 
with VAPB in different patch modes. R) Relative currents of HCN2
HAEx alone or with VAPB. 
S) Relative surface expression of HCN2
HAEx expressed alone or with VAPB, analyzed as 
Relative Light Units (RLUs). T) Relative currents of HCN2 expressed alone or with VAPB or 
VAPB
P56S
. All data are presented as mean ± s.e.m.. The number of cells (n) are indicated in 
the bar graphs. *, P < 0.05; **; P < 0.01; ***, P < 0.001 using an unpaired Student´s T-test, 
except for panels I), J), N), M) and T) using a Mann-Whitney-U-test. 
 
Figure 2. Domains mediating the interaction of VAPB with HCN2. A) Schematic illustration 
of a HCN subunit. The cyclic-nucleotide binding-domain (CNBD) and some of the truncation 
constructs studied are indicated. B) All truncation constructs showed a positive interaction, 
evident from growth on -LWHA drop out medium. C) Representative current traces and the 
relative currents for different C-terminal deletions expressed alone or with VAPB. D) 
Representative current traces and the relative current amplitudes for the N-terminal truncated 
NTK
HCN2 expressed alone or with VAPB. E) Relative current amplitudes of 
NTK
HCN2
HAEx 
(extracellular HA-tag) expressed alone or with VAPB. F) Relative surface expression of 
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NTK
HCN2
HAEx expressed alone or with VAPB analyzed as Relative Light Units (RLUs). G) 
Schematic illustration, representative traces and currents of a HCN2 channel chimera with the 
N-terminus of HCN4 (
HCN4-N
HCN2) expressed alone or with VAPB. H) Relative currents of 
HCN2 expressed alone or co-expressed with VAPB (1.7 ± 0.1), TM
VAPB
 (1.6 ± 0.2), the major 
sperm domain (MSP
VAPB
), the MSP with half of the coiled-coil (CC) domain (MSP-
CC0.5
VAPB
) or with the complete CC domain (MSP-CC
VAPB
). I) Relative current amplitudes of 
HCN2
HAEx expressed alone or with TM
VAPB
 (1.3 ± 0.1) and J) the respective changes in the 
relative surface membrane expression analyzed as RLUs, using a single cell 
chemiluminescence assay (TM
VAPB
 1.8 ± 0.2). All data are presented as mean ± s.e.m.. The 
number of experiments (n) are indicated in the respective bar graphs. *, P < 0.05; **, P < 
0.01; ***, P < 0.001 using an unpaired Student´s T-test, except for panels C), D), F), G), H) 
and J) using a Mann-Whitney-U-test and for panel i using Welch’s T-test. 
 
Figure 3. VAPB determines surface expression and dendritic localization of HCN2. A) Live 
cell imaging of HeLa cells transfected with a N-terminally EGFP-tagged HCN2 carrying an 
extracellular HA-epitope (
EGFP
HCN2
HAEx) alone or co-transfected with VAPB or the 
transmembrane segment of VAPB (TM
VAPB
). B) Chemiluminescence assays of fixed non-
permeabilized HeLa cells, analyzing the surface expression as Relative Light Units (RLUs) 
for 
EGFP
HCN2
HAEx alone and after co-transfection with VAPB (1.6 ± 0.1). Upper inset 
illustrates a representative control Western blot showing an unaltered HCN2 protein 
expression. C) Chemiluminescence surface expression assay as in B), but using TM
VAPB
 (1.6 
± 0.1). D) Immunocytochemistry of 
HA
VAPB transfected cortical neurons. Endogenous 
HCN2 (green) is co-localizing (white) with 
HA
VAPB (magenta) in the soma and dendrites. 
Anti MAP2-staining illustrating an intact neuronal network and dendrites (blue). E) 
Immunocytochemistry experiment as in d, but transfecting the ALS8 mutation 
HA
VAPB
P56S
 
(magenta), leading to an aggregation of VAPB
P56S
 in the soma of the neurons. Also HCN2 
fluorescence (green) was focused in the soma and dendritic localization was lost, despite an 
intact neuronal network (α-MAP2, blue). All data are presented as mean ± s.e.m.. The number 
of experiments (n) are indicated in the respective bar graphs. **; P < 0.01 using an unpaired 
Student´s T-test. Scale bars for A), D) and E), 20 µm. 
 
Figure 4. Co-distribution of VAPs with HCN2 and contribution to thalamic Ih. A)-E), 
Distribution of HCN2, VAPB and VAPA mRNA in mouse brain and spinal cord. In situ 
hybridization analysis of HCN2, VAPB and VAPA using digoxigenin-labeled riboprobes, 
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revealing mRNA expression of VAPB in A) cortical areas B) hippocampus C) thalamus D) 
cerebellum (arrows point to interneurons in the granular layer) and E) spinal cord. Note the 
overlapping distribution of VAPB with HCN2 and VAPA mRNA. Pir, piriform cortex; Am, 
amygdala; ic, internal capsule; Th, thalamus; CA, cornu ammonis; DG, dentate gyrus; LG, 
lateral geniculate ncl.; VB, ventrobasal thalamus; RTh, reticular thalamic ncl.; Sth, 
subthalamic ncl.; Hb, habenulae; gcl, granule cell layer; pcl, purkinje cell layer; m, molecular 
cell layer; DH, dorsal horn; VH, ventral horn. F) Representative current traces elicited in slice 
patch clamp experiments of the ventrobasal thalamus (VB) of wild-type animals (control) and 
VAPB
-/-
 mice. G) The Ih current was significantly reduced in VAPB
-/-
 mice (15.4 ± 1.1 
pA/pF) compared to control animals (22.2 ± 2.3 pA/pF). H) Average activation curves of the 
VB Ih current for control and VAPB
-/-
 mice. V1/2 of activation for
 
control (-91.6 ±1.3 mV, n = 
8) and VAPB
-/-
 (-87.5 ± 1.2 mV, n = 7). All data are presented as mean ± s.e.m.. The number 
of experiments (n) are indicated in the respective bar graphs. *, P < 0.05 using an unpaired 
Student´s T-test. Scale bars, 500 µm, except for D), 100 µm. 
 
Figure 5. Bradycardia in knock-down zebrafish embryos and VAPB
-/-
 mice. A) Zebrafish 
embryos at 72 hours post fertilization (hpf). Control-injected and Morpholino-antisense (MO) 
injected embryos against VAPA (
MO
VAPA) or VAPB (
MO
VAPB) exhibit no significant 
abnormalities (left), in particular no structural heart defects (right). Note a light cardiac edema 
in 
MO
VAPB and a strong edema in 
MO
VAPA. B) Heart rate in beats per minute (bpm) of 
control and 
MO
VAPA, 
MO
VAPB or 
MO
VAPA/B injected zebrafish embryos at 72 hpf. C) 
Representative examples of calcium transients (relative fluorescence intensity) in the cardiac 
atrium (black) and cardiac ventricle (gray) of control-injected zebrafish at 72 hpf, displaying a 
regular atrio-ventricular propagation of excitation from atrium to ventricle in a 1:1-ratio. D)-
F), Representative calcium transients recorded in 
MO
VAPA/B double knock-down morphants, 
illustrating D) and E) strongly reduced heart rates with variable frequency. F) Representative 
example of atrial and ventricular calcium measurements from a 
MO
VAPA/B morphant with a 
2:1 atrio-ventricular block, where only every second atrial excitation leads to a ventricular 
excitation. A)-F), Data were obtained from three independent batches of injections. G) Heart 
rate in beats per minute (bpm) of VAPB
-/-
 mice compared to wild-type littermates (control), 
analyzed by tail-cuff measurements. H) Representative surface electrocardiogram (ECG) 
recordings of VAPB
-/-
 mice and their wild-type littermates (control). ECG of VAPB
-/-
 mice 
show bradycardia and an increased T-wave amplitude. I)-N), Analyses of the ECG parameters 
of VAPB
-/-
 mice. I), Heart rate in beats per minute (bpm). J) PQ interval (PQ) duration. K) 
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QRS complex (QRS) duration. L) Frequency corrected QT interval (QTc). M) Frequency 
corrected Tpeak to Tend duration (Tp-Tec). N) T-wave amplitude (JTp). All data are presented as 
mean ± s.e.m.. The number of animals (n) is indicated in the respective bar graphs. *, P < 
0.05; **, P < 0.01; ***, P < 0.001 using an unpaired Student´s T-test, except for panels B) and 
I) using Welch’s T-test. Scale bars for A), 500 µm, for C)-F), 500 ms and for H), 100 ms. 
 
Figure 6. VAPB modulates If of spontaneously beating cardiac HL-1 cells. A) 
Immunocytochemistry of VAPB in HL-1 cells. B) Western blot illustrating the knock-down of 
VAPB expression in HL-1 cells by shRNA transfection. Control, HL-1 cells transfected with 
scrambled shRNA. C) Representative If currents of HL-1 cells under control conditions and 
after VAPB transfection. D) Percentage of HL-1 cells containing If under control conditions 
(38%) and after VAPB transfection (58%). E) Beating frequency under control conditions 
(158 ± 4) and after VAPB transfection (179 ± 4), analyzed by optical counting of contractions 
in original Claycomb medium containing norepinephrine (60). F) Accelerated activation 
kinetics of VAPB transfected HL-1 cells (n = 9 - 10). G) Activation curves of HL-1 cells 
under control conditions (n = 10) and after VAPB transfection (n = 11). H) Positive shift in 
the V1/2 of activation of If recorded in VAPB transfected HL-1 cells. Control (scrambled 
shRNA), -90.3 ± 3.4 mV (n = 10); VAPB transfected, -79.6 ± 2.7 mV (n = 11). I) 
Representative action potential measurements of wild-type HL-1 and shRNA transfected cells 
(shVAPB). J) Analysis of the diastolic depolarization (DD duration). K) Beating frequency of 
HL-1 cells under control conditions and after VAPB knock-down. L) VAPB knock-down 
slows the activation kinetics (n = 5) of endogenous If currents. M) Transfection of shRNA (n 
= 5) shifts the voltage-dependence of activation (V1/2) of If to more negative potentials (n = 6). 
N) V1/2 values for control (scrambled shRNA) were -88.2 ± 3.1 mV (n = 6) and for shRNA-
transfection (shVAPB) -96.2 ± 2.3 mV (n = 5), respectively. I)-J), Scrambled shRNA was 
used as control. All data are presented as mean ± s.e.m.. The number of experiments (n) are 
indicated in the bar graphs. *, P < 0.05; **, P < 0.01; ***, P < 0.001 using an unpaired 
Student´s T-test, except for panels E), F), J), K), L) and N) using a Mann-Whitney-U-test. 
Scale bars for A), 20 µm.  
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